Get the Stockscreener App
0.2498
20.10%
0.0418
After Hours:
.25
0.0002
+0.08%
Biorestorative Therapies Inc stock is traded at $0.2498, with a volume of 10.66M.
It is up +20.10% in the last 24 hours and up +8.66% over the past month.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
See More
Previous Close:
$0.208
Open:
$0.2087
24h Volume:
10.66M
Relative Volume:
1.27
Market Cap:
$6.36M
Revenue:
$359.70K
Net Income/Loss:
$-14.24M
P/E Ratio:
-0.1525
EPS:
-1.6376
Net Cash Flow:
$-10.91M
1W Performance:
+36.06%
1M Performance:
+8.66%
6M Performance:
-77.29%
1Y Performance:
-84.95%
1-Day Range:
$0.2079
$0.2899
1-Week Range:
$0.1593
$0.2899
52-Week Range:
$0.1593
$2.045
Biorestorative Therapies Inc Stock (BRTX) Company Profile
Name
Biorestorative Therapies Inc
Sector
Industry
Phone
(631) 760-8100
Address
40 MARCUS DRIVE, MELVILLE
Compare BRTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BRTX
Biorestorative Therapies Inc
|
0.2498 | 5.30M | 359.70K | -14.24M | -10.91M | -1.6376 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biorestorative Therapies Inc Stock (BRTX) Latest News
Biorestorative Therapies says topline phase 2 data for BRTX-100 expected in Q2 2027 - marketscreener.com
Biorestorative Therapies Says Topline Phase 2 Data For BRTX-100 Expected In Q2 2027 - TradingView
BioRestorative Therapies Completes Patient Dosing in Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease - Quiver Quantitative
Stem cell back pain shot finishes Phase 2, topline data due 2027 - Stock Titan
BRTX Should I Buy - Intellectia AI
BioRestorative Therapies (BRTX) Surges 13.66% as Stock Tests Key Resistance at $0.20Corrective Wave - Newser
What makes Biorestorative Therapies (BRTX) a new buy stock - MSN
Biorestorative Therapies, Inc. (BRTX) reports Q1 loss, misses revenue estimates - MSN
Auctus Fund (BRTX) discloses 2.7M-share, 9.9% position including warrants - Stock Titan
What Makes Biorestorative Therapies (BRTX) a New Buy Stock - Yahoo Finance
MSN Money - MSN
Certain Series B Preferred Stock of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. - marketscreener.com
Certain Warrants of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. - marketscreener.com
Certain Options of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. - marketscreener.com
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
BioRestorative Therapies Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BioRestorative Therapies, Inc. 1Q 2026: Revenue $23.2K, EPS $(0.12) — 10-Q Summary - TradingView
BioRestorative Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioRestorative Therapies (BRTX) Q1 2026 loss, cash burn and Nasdaq bid-price risk - Stock Titan
BioRestorative presents data on stem cell-derived exosomes By Investing.com - Investing.com India
BioRestorative presents data on stem cell-derived exosomes - Investing.com UK
BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals - The Manila Times
Biorestorative Therapies Presents New Preclinical Data on Source-Specific Exosome Functionality and Commercial Applications in Biocosmeceuticals - marketscreener.com
TradingKey - TradingKey
BioRestorative Therapies Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease - Orthopedics This Week
Biorestorative Therapies' BRTX-100 shows sustained pain & functional improvements in chronic lumbar disc disease - marketscreener.com
BioRestorative Therapies’ BRTX-100 Phase 2 Data Shows Continued Pain Reduction in Lumbar Disc Disease Patients - geneonline.com
BioRestorative Therapies announced that its 52-week clinical study cohort has been expanded to 25 patients. - Bitget
Back pain stem cell study shows 52% had 50% pain and function gains - Stock Titan
BRTX Stock Price, Quote & Chart | BIORESTORATIVE THERAPIES INC (NASDAQ:BRTX) - ChartMill
BioRestorative Therapies Boosts Executive Compensation and Equity Incentives - TipRanks
Biorestorative Therapies | 8-K: Current report - Moomoo
BioRestorative Therapies awards cash bonuses to CEO Lance Alstodt, VP Francisco Silva and CFO Robert Kristal - TradingView
BioRestorative (NASDAQ: BRTX) details 2025 executive pay and bonuses - Stock Titan
Biorestorative Therapies | EFFECT: Others - Moomoo
Biorestorative Therapies | 424B3: Prospectus - Moomoo
BioRestorative Therapies (NASDAQ: BRTX) registers 15.29M warrant shares - Stock Titan
BioRestorative to present clinical, preclinical data at ISCT - Investing.com UK
BioRestorative to present clinical, preclinical data at ISCT By Investing.com - Investing.com Nigeria
BioRestorative Therapies Presents New Data on MSC-Derived Programs at ISCT 2026 Annual Meeting - Quiver Quantitative
BioRestorative brings two programs to Dublin, including Phase 2 spine trial data - Stock Titan
Biorestorative Therapies Inc Presents New Data at ISCT 2026 Highlighting Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Biocosmeceutical Platform - marketscreener.com
Biorestorative Therapies, Inc. (BRTX) reports Q4 loss, lags revenue estimates - MSN
BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform - The Manila Times
[EFFECT] BioRestorative Therapies, Inc. SEC Filing - Stock Titan
Here's why Biorestorative Therapies (BRTX) looks ripe for bottom fishing - MSN
Biorestorative Therapies | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filingmoomoo - Moomoo
BioRestorative Therapies (NASDAQ: BRTX) files S-1/A amendment; counsel opinion added - Stock Titan
Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing - Yahoo! Finance Canada
Biorestorative Therapies Inc Stock (BRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):